The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer

Jun Guan, Xiaojun ChenFrontiers in Endocrinology 2022 · DOI

Introduction

Progestin therapy serves as the primary fertility-sparing treatment for women diagnosed with atypical endometrial hyperplasia (AEH) and early-stage endometrioid endometrial cancer (EEC). While effective for many, approximately 15–25% of patients fail to achieve a complete response (CR), ultimately requiring definitive surgery and the subsequent loss of fertility. Metformin, a well-established biguanide used for type 2 diabetes, has emerged as a potential adjunctive therapy due to its anti-cancer properties and metabolic benefits. This review examines the current evidence regarding the combination of metformin and progestin in fertility-preserving oncology.

The Clinical Challenge

For young women desiring childbearing, the standard of care involves high-dose progestins to reverse endometrial lesions. However, this treatment often induces side effects such as weight gain, which can worsen the metabolic dysfunction—including obesity and insulin resistance—that frequently drives the development of endometrial cancer. There is a critical need for supplemental treatments that can improve CR rates, reduce recurrence, and manage the underlying metabolic risk factors.

Molecular Mechanisms of Metformin

Metformin exerts its anti-tumor effects through several key pathways:

  • Pathway Inhibition: It inhibits the PI3K-AKT-mTOR signaling pathway, which is frequently dysregulated in endometrial cancer.
  • AMPK Activation: By activating adenosine monophosphate-activated protein kinase (AMPK), metformin induces tumor suppressor genes and inhibits cell proliferation.
  • Progesterone Sensitization: Crucially, metformin may increase the expression of progesterone receptors (PR) in endometrial tissues, potentially overcoming progestin resistance and enhancing the efficacy of the primary treatment.

Clinical Outcomes: Complete Response and Relapse

The clinical evidence for metformin's efficacy remains mixed. In a notable Phase II randomized controlled trial (RCT) of 150 patients, the combination of metformin and megestrol acetate showed a borderline-significantly higher CR rate at 16 weeks (34.3%) compared to megestrol acetate alone (20.7%). However, this statistical advantage diminished by the 32-week mark as the control group caught up.

The most compelling data involves cancer relapse. Meta-analyses and retrospective studies suggest that metformin may significantly reduce recurrence rates. One study reported a relapse rate of 17.4% in metformin users versus 25% in non-users, with a pooled odds ratio of 0.46 across multiple studies. This suggests that metformin may be particularly effective as a maintenance therapy to prevent the return of disease after initial clearance.

Fertility and Safety

Current data do not show a significant difference in pregnancy outcomes between patients receiving metformin and those who do not (approximately 48% vs. 42% in clinical trials). From a safety perspective, metformin is generally well-tolerated. The most frequent adverse effects are mild gastrointestinal issues, such as grade 1-2 diarrhea, which typically do not require treatment discontinuation.

Limitations and Future Directions

The current body of research is limited by high heterogeneity in study design, including varying metformin dosages (ranging from 500mg to 2250mg daily), inconsistent treatment durations, and small sample sizes. Furthermore, the frequent use of hysteroscopy for lesion removal may confound results by surgically eliminating the tissue that the pharmacological intervention is intended to treat.

High-quality, large-scale Phase III trials, such as the ongoing FELICIA trial, are essential to validate these findings. Future research must establish standardized dosing protocols and determine whether specific patient subgroups (e.g., those with high BMI or insulin resistance) benefit more from adjunctive metformin therapy.

Conclusion

While metformin shows promise as a multi-pronged adjunctive therapy for AEH and EEC, there is currently insufficient evidence to recommend its routine use in fertility-preserving protocols. Its potential to reduce relapse rates and improve metabolic health is significant, but definitive clinical recommendations await the results of more robust, well-powered trials.

Summary updated

Abstract

Progestin therapy is the main fertility-sparing treatment for women with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH). However, still 15-25% of these women failed to achieve complete response (CR) and then lost their fertility after definitive surgery. Metformin has been demonstrated to play an anti-cancer role in multiple cancers including EC. Several studies also suggested metformin had potential benefit in improving the therapeutic outcome of fertility-preserving treatment alongside with progestin. This review has discussed existed evidence regarding the effect of metformin combined with progestin for women with AEH and EC who desire childbearing. Nevertheless, the therapeutic effect of metformin varied in different studies due to the high heterogeneity in the patient's characteristics, the inconsistency in dose and treatment duration of metformin, the combined use of hysteroscopy, the insufficient sample size and underpowered study-design. Therefore, care should be taken when interpreting the current results on this issue. Till now, there is still no strong evidence supporting the use of metformin in fertility-preserving treatment in AEH and EEC patients. Further research is needed to provide high-quality data to validate the role of metformin as adjunctive therapy alongside with progestin to preserve fertility for AEH and EEC patients.
BibTeX
@inproceedings{guan2022present,
  author = {Jun Guan and Xiaojun Chen},
  title = {{The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer}},
  booktitle = {Frontiers in Endocrinology},
  year = {2022},
  doi = {10.3389/fendo.2022.1041535},
}
Figure